Skip to main content

Advertisement

Table 2 Factors associated with poor-compliance in subjects of total cohort and subgroup

From: Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review

  Total subjects at year 1 (n = 333) Subgroup subjects at year 2 (n = 174)a
Risk factors n (%) Univariate analysis Multivariate analysis n (%) Univariate analysis Multivariate analysis
  OR 95% CI p-value OR 95% CI p-value   OR 95% CI p-value OR 95% CI p-value
Age   1.03 (1.01-1.05) 0.007 1.02 (0.99-1.05) 0.132   0.97 (0.94-0.99) 0.045 0.97 (0.94-1.01) 0.100
First prescribed by           
 Rheumatologist 55 (34.6) 1.0 (referent)   1.0 (referent)   24 (48.0) 1.0 (referent)   1.0 (referent)
 Orthopedist 64 (40.3) 2.67 (1.58-4.53) 0.000 2.30 (1.26-4.22) 0.007 13 (26.0) 1.38 (0.60-3.14) 0.447 1.52 (0.58-3.96) 0.394
 Others 40 (25.2) 1.19 (0.70-2.03) 0.525 1.12 (0.62-2.05) 0.709 13 (26.0) 0.85 (0.39-1.86) 0.679 0.86 (0.35-2.14) 0.746
DXA 13 (8.2) 0.52 (0.32-0.85) 0.008 0.51 (0.28-0.93) 0.029 17 (34.0) 0.97 (0.49-1.94) 0.932 0.94 (0.39-2.26) 0.895
Vertebroplasty 5 (3.1) 0.91 (0.27-3.04) 0.877 0.59 (0.15-2.30) 0.450 1 (2.0) 0.49 (0.06-4.27) 0.515 0.71 (0.07-7.08) 0.769
Fracture site           
 Spine fracture 131 (82.4) 1.40 (0.81-2.40) 0.225 1.54 (0.45-5.29) 0.489 36 (72.0) 0.68 (0.32-1.45) 0.320 0.37 (0.05-2.95) 0.345
 Hip fracture 27 (17.0) 1.49 (0.81-2.76) 0.204 1.21 (0.41-3.54) 0.731 7 (14.0) 1.28 (0.48-3.36) 0.620 0.47 (0.06-3.50) 0.457
 Others fracture 13 (8.2) 1.85 (0.75-4.58) 0.185 1.88 (0.69-5.10) 0.216 3 (6.0) 1.52 (0.35-6.61) 0.577 1.16 (0.22-6.23) 0.863
Tobacco useb 1 (0.6) -- 0.477 0.00 (0.00) 1.000 0 (0) -- -- -- --
Alcohol use 1 (0.6) 1.10 (0.07-17.65) 0.949 0.00 (0.00) 1.000 1 (2.0) 4.09 (0.00) 1.000 1.37 (0.00) 1.000
Malignancy 11 (6.9) 1.00 (0.43-2.34) 0.994 0.98 (0.39-2.45) 0.960 3 (6.0) 0.82 (0.21-3.15) 0.767 0.78 (0.19-3.27) 0.734
Cardiac disease 32 (20.1) 1.94 (1.06-3.56) 0.032 1.87 (0.93-3.75) 0.079 7 (14.0) 1.39 (0.52-3.72) 0.512 1.79 (0.58-5.49) 0.311
Respiratory disease 19 (11.9) 1.34 (0.66-2.71) 0.413 1.22 (0.57-2.63) 0.610 4 (8.0) 0.81 (0.25-2.65) 0.729 0.72 (0.20-2.56) 0.611
Neuropsychiatric disease 30 (18.9) 1.21 (0.69-2.14) 0.505 0.89 (0.47-1.70) 0.732 6 (12.0) 0.63 (0.24-1.67) 0.354 0.68 (0.23-2.02) 0.485
Chronic kidney disease 12 (7.5) 1.34 (0.56-3.19) 0.509 1.35 (0.51-3.58) 0.548 2 (4.0) 0.60 (0.12-2.95) 0.533 0.66 (0.12-3.62) 0.636
Endocrine/metabolic 29 (18.2) 1.54 (0.85-2.81) 0.157 1.81 (0.90-3.64) 0.095 6 (12.0) 0.92 (0.34-2.51) 0.871 0.82 (0.26-2.60) 0.734
Hypertension 49 (30.8) 0.83 (0.52-1.31) 0.411 0.62 (0.37-1.06) 0.083 21 (42.0) 1.52 (0.77-2.99) 0.224 1.62 (0.77-3.43) 0.207
Rheumatoid arthritis 3 (1.9) 0.22 (0.06-0.78) 0.011 0.19 (0.04-0.81) 0.025 4 (8.0) 0.99 (0.30-3.32) 0.989 0.81 (0.17-3.89) 0.790
Hepatobiliary disease 6 (3.8) 0.42 (0.16-1.10) 0.075 0.44 (0.16-1.25) 0.124 2 (4.0) 0.36 (0.08-1.64) 0.185 0.45 (0.09-2.33) 0.340
Steroid use 21 (13.2) 0.73 (0.40-1.34) 0.307 1.48 (0.68-3.22) 0.320 10 (20.0) 1.30 (0.56-3.02) 0.541 1.02 (0.31-3.29) 0.980
  1. OR odds ratio, CI confidence interval, Serum creatinine >1.4 mg/dl; aSubjects with MPR ≥ 80% at year 1; bNo one smoked, so the factor cannot be estimated; All comparisons denote present vs. absent.